...Leslie Riddle; Jennifer Elyse James; Arash Naeim; Lisa Madlensky; Susie Brain; Diana DeRosa; Martin Eklund; Allison Stover Fiscalini; Diane Heditsian; Barbara Koenig; Katherine Ross; Leah P. Sabacan; Barry Tong; Neil Wenger; Galen Joseph Introduction: Risk-based breast cancer screening aims...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2024 Breast cancer BRCA1 BRCA2 Community-based participatory research...

...Annelie Augustinsson; Carolina Ellberg; Ulf Kristoffersson; Håkan Olsson; Hans Ehrencrona Swedish national breast cancer guidelines recommend that all women diagnosed with breast cancer (BC) at the age of 35 years or younger should be referred to their regional oncogenetic clinic for genetic...

... not to be at increased risk of being a BRCA mutation carrier; the majority of those screened, recall, understand and accept the implications of these results for breast cancer risk. Methods: We conducted an online survey with women ( n = 148) who screened negative on a brief HBOC screener. Results: While women tended...

...Kay Schreuder; Anne Kuijer; Sanne Bentum; Thijs van Dalen; Sabine Siesling Background: The nationwide use of the 21-gene recurrence score (21-RS) and implications regarding chemotherapy administration in relation to clinical risk in early breast cancer patients are investigated. Methods: Breast...

...Anne Kuijer; Kay Schreuder; Sjoerd G. Elias; Carolien H. Smorenburg; Emiel J.T. Rutgers; Sabine Siesling; Thijs van Dalen Background: Breast cancer guidelines suggest the use of gene expression profiles (GEPs) in estrogen receptor-positive (ER+) breast cancer patients in whom controversy exists...

...Jalila Jbilou; Norrin Halilem; Jolyane Blouin-Bougie; Nabil Amara; Réjean Landry; Jacques Simard Objectives: This paper aims to identify relevant potential predictors of medical genetic counseling for breast cancer (MGC-BC) in primary care and to develop a comprehensive questionnaire to study MGC...

... a key determinant in breast cancer outcomes. Our study examined patients' beliefs about how the CYP2D6 genotype would affect their prognoses. Methods: Women enrolled in a pharmacogenomic clinical trial and on tamoxifen for prevention or treatment of breast cancer underwent CYP2D6 genotyping (EM...

...V. Seror; P. Marino; F. Bertucci; J. Mancini; J.-M. Extra; J.-M. Ferrero; T. Bachelot; P. Viens; C. Julian-Reynier Background/Aims: Incorporating gene expression profiling into routine clinical practices is beginning to be recommended as part of breast cancer treatment. The aim of the present study...

..., such as not informing patients or their families of potential genetic risk. A similar outcome is also of concern in the case of risk prediction models used for hereditary breast cancer. Results: No legal case has directly addressed the use of risk prediction models. However, as genetic medicine and risk prediction...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Breast cancer Cultural identity Ethnic identity Genetic testing Racial identity National Institutes...

... regression was used to compare prevalence by demographic factors. Results: A positive family history among first-degree relatives was reported by 10.9% (95% Confidence Interval, CI = 8.8–13.3) of respondents for breast cancer, 5.1% (95% CI = 3.9–6.7) for colorectal cancer, 7.0% (95% CI = 5.2–9.4...

...L. Henneman; D.R. Timmermans; C.M. Bouwman; M.C. Cornel; H. Meijers-Heijboer Background: Population breast cancer screening programs by mammography are offered to women based on age. It has been suggested that a screening program based on genetic risk profile could be more effective by targeting...